Headlines about USANA Health Sciences (NYSE:USNA) have trended somewhat positive recently, according to Accern. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. USANA Health Sciences earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.4186441349984 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news headlines that may have effected Accern’s scoring:
- USANA Health Sciences TMF Higher On Launch of New Products in Canada (guerillastocktrading.com)
- USANA Health Sciences, Inc. (USNA) to Release Earnings on Monday (americanbankingnews.com)
- USANA Launches Prenatal CellSentials, MagneCal D In Canada … – Markets Insider (markets.businessinsider.com)
- USANA Health Sciences : Launches Two New Products in Canada (4-traders.com)
USANA Health Sciences (NYSE USNA) traded down 1.13% during mid-day trading on Tuesday, reaching $61.15. The company’s stock had a trading volume of 83,483 shares. USANA Health Sciences has a 52 week low of $52.55 and a 52 week high of $74.72. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of 15.88 and a beta of 1.09. The company’s 50-day moving average price is $58.25 and its 200 day moving average price is $60.24.
USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $0.98 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.08). The business had revenue of $257.10 million during the quarter, compared to analyst estimates of $273.61 million. USANA Health Sciences had a return on equity of 28.93% and a net margin of 9.47%. The business’s revenue was down .5% on a year-over-year basis. During the same quarter last year, the firm earned $2.07 EPS. On average, equities analysts forecast that USANA Health Sciences will post $3.79 earnings per share for the current fiscal year.
USANA Health Sciences declared that its board has approved a stock buyback program on Tuesday, July 25th that allows the company to repurchase $64.60 million in shares. This repurchase authorization allows the company to reacquire up to 46% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company’s leadership believes its stock is undervalued.
Several brokerages recently issued reports on USNA. BidaskClub cut USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, June 20th. Pivotal Research lowered their target price on USANA Health Sciences from $75.00 to $70.00 and set a “buy” rating for the company in a report on Wednesday, July 26th.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://stocknewstimes.com/2017/10/17/usana-health-sciences-usna-receiving-somewhat-favorable-media-coverage-study-finds.html.
In related news, Director Myron W. Wentz sold 40,000 shares of the business’s stock in a transaction on Tuesday, October 3rd. The shares were sold at an average price of $57.54, for a total transaction of $2,301,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Gilbert A. Fuller sold 1,483 shares of the business’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $57.67, for a total transaction of $85,524.61. Following the transaction, the director now owns 1,483 shares of the company’s stock, valued at approximately $85,524.61. The disclosure for this sale can be found here. In the last 90 days, insiders sold 386,340 shares of company stock valued at $22,270,913. Insiders own 53.20% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. The Company operates as a direct selling company in two geographic regions: Americas and Europe, and Asia Pacific, which includes three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.